Pharma Market Access Insights - from Petauri Evidence cover art

Pharma Market Access Insights - from Petauri Evidence

Pharma Market Access Insights - from Petauri Evidence

Written by: Petauri Evidence
Listen for free

About this listen

We explore news and insights from global healthcare markets, advising how pharma and medtech need to respond and adapt their market access strategy in light of the latest insights from our experts. The podcast features insights from our associates across global healthcare, along with thought leadership from the market access and HEOR experts at Petauri Evidence.

© 2025 Mtech Access
Biological Sciences Economics Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • The Evolving NHS – An ICS Chief Pharmacist’s Perspective
    Nov 17 2025

    Send us a text

    What does the evolving NHS landscape look like through the eyes of a Chief Pharmacist, and how are integrated care system (ICS) pharmacy teams responding?

    In this Petauri Evidence NHS Whispers session, we put your questions to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS), as he shares how he and his colleagues are responding to the changing NHS environment. From system pressures and financial constraints to prescribing priorities and service redesign, Yousaf explored how ICS pharmacy teams are adapting, and what this means for industry partners.

    This episode was first broadcast as live webinar on: Friday 24th October 2025.

    Learn more about this episode at https://petauri.com/insights/evolving-nhs-ics-chief-pharmacists-perspective/

    Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

    Show More Show Less
    31 mins
  • First to Market: Unlocking Switzerland’s Pharma Potential
    Nov 12 2025

    Send us a text

    What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing?

    This episode explores Switzerland’s potential as an early launch market.

    In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed Dr Elisabeth Brock (Independent expert in market access in Switzerland), who has extensive experience in Swiss healthcare, including regulatory and payer engagement, dossier preparation for the Swiss Specialities List (SL), and strategic launch planning.

    Together, we explored what global market access teams need to know about launching in Switzerland – from regulatory routes and pricing frameworks to the nuances of payer expectations and evidence generation.

    We discussed:
    - What makes Switzerland attractive as a first-launch market
    - Key differences between Swiss and European Union (EU) market access pathways
    - How to prepare for inclusion on the SL and what “economically efficient pricing” really means
    - The role of cantonal (state) variation and decentralised healthcare in shaping access
    - How Swiss decisions may be influenced by the EU’s JCA
    - What global teams can learn from Swiss strategy to inform broader launch planning

    This episode was first broadcast as a live webinar on Thursday 16th October 2025

    Learn more at https://petauri.com/insights/market-access-switzerland/

    Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

    Show More Show Less
    45 mins
  • Q&A Webinar: The Evolving NHS Landscape in England – From Policy to Practice
    Oct 13 2025

    Send us a text

    In this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to:
    - Sarah Everest Ford (Programme Director, Health and Care Partnership)
    - Patrick McGee (Deputy Programme Director for Pathology, Lancashire & South Cumbria)
    - Prof. Phil Richardson (Former Dorset ICS System Commissioning Director; now Chief Innovation Officer, Petauri Evidence)

    Together, they explore the implications of changing NHS structure and policy, and what this means for your market access, stakeholder engagement, and product innovation strategies.

    This episode was first broadcast as a live webinar on 19th September 2025. Some to the topics discussed may evolve over time. This session was shaped by your questions. Key themes included:
    - Evolving NHS structures, policies, and practices – and what this means for industry
    - Strategic commissioning: where will it happen, and who will lead it?
    - The 10 Year Plan and its implications for innovation and access
    - How industry can adapt to new engagement models and financial constraints
    - What the shift to integrated neighbourhoods means for product rollout and service design

    Learn more at: https://petauri.com/insights/evolving-nhs-landscape-policy-to-practice/

    For support with navigating the evolving NHS and launching new medicines and products in England, please email evidence@petauri.com.

    Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

    Show More Show Less
    1 hr
No reviews yet